Hoth Therapeutics (HOTH) has entered into a Master Services Agreement with Aronnax for its HT-KIT cancer therapeutic. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT being developed for the treatment of mast cell-derived cancers and anaphylaxis and previously received Orphan Drug Designation from FDA.
"This further analysis will help us with that process, finalizing the protocols in our upcoming IND-enabling study. We are pleased to further engage Aronnax and ITR Laboratories on these key studies given their reputation for IND-enabling studies," stated Robb Knie, CEO.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.